This study showed that ASTN treatment dramatically ameliorates HFD-induced frequency and cell number of α-SMA+Col-1+ myofibroblasts or activated HSCs during NASH progression. The gene discussed is ASTN1; the disease is metabolic dysfunction-associated steatohepatitis.